Business Description
NeuroSense Therapeutics Ltd
ISIN : IL0011809592
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 18.59 | |||||
Equity-to-Asset | -0.59 | |||||
Debt-to-Equity | -0.08 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -47 | |||||
3-Year EPS without NRI Growth Rate | -56.2 | |||||
3-Year FCF Growth Rate | -113.4 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 15.03 | |||||
9-Day RSI | 25.69 | |||||
14-Day RSI | 33.61 | |||||
6-1 Month Momentum % | 260.55 | |||||
12-1 Month Momentum % | -15.42 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.84 | |||||
Quick Ratio | 0.84 | |||||
Cash Ratio | 0.76 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12 | |||||
Shareholder Yield % | 0.37 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -1152.67 | |||||
ROA % | -191.35 | |||||
ROIC % | -3014.96 | |||||
ROC (Joel Greenblatt) % | -4077.06 | |||||
ROCE % | -337.74 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -1.72 | |||||
EV-to-EBITDA | -1.72 | |||||
EV-to-FCF | -2.28 | |||||
Earnings Yield (Greenblatt) % | -58.14 | |||||
FCF Yield % | -39.78 |